

Transdermal Drug Delivery

Patches, Gels, Active Systems, Therapeutics, Markets & Forecasts



Greystone Associates is pleased to announce the publication of a new market study. **Transdermal Drug Delivery: Patches, Gels, Active Systems, Therapeutics, Markets and Forecasts** is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the drug delivery sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for transdermal drug delivery. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Noninvasive Delivery for a Growing List of Indications

Created as an alternate route of administration to improve patient compliance and reduce prescription drug side effects, transdermal drug delivery is rapidly becoming an important healthcare product category. Transdermal delivery offers the advantages of ease of use, painlessness, disposability, control of drug delivery and avoidance of first-pass metabolism by the liver. Advances in synthetic materials and package design have led to patches and formulations that are more esthetically acceptable and that are capable of delivering sustained dosing of active compounds for several days in a smaller package.

Transdermal products relying on passive transport mechanisms have been limited in their ability to deliver new classes of drugs, but formulations employing penetration enhancers, and patch designs incorporating microporation and energy-assisted delivery are expanding the range of drugs that can be effectively delivered transdermally. Growth in demand for drug patches is being driven by several factors – factors with strong demographic and population trend underpinnings. Further improvements to transdermal transport and the introduction of new patch designs and APIs will keep this segment expanding through 2012.

Report Value Matrix




Table of Contents

Executive Summary

- The Evolving Drug Delivery Marketplace
- Factors Favoring Non-traditional Routes of Administration
- Transdermal Delivery Demand Drivers
- Factors Limiting Growth
- Competitive Landscape
- Key Forecasts

Transdermal Drug Delivery Dynamics

- Passive Patches
 - Patch Design & Technology
 - Patch Construction
 - Patch Economics
 - Sourcing and Contract Manufacturing
 - Patch Manufacturer Profiles
- Transdermal Gels
 - Formulation Technology
 - IP and Proprietary Technologies
 - Limitations of Transdermal Gels
- Active Transdermal Delivery
 - Active Transdermal Technology
 - Electrical Current
 - Iontophoresis
 - Electroporation
 - Microporation
 - Laser Ablation
 - Mechanical Microneedle Arrays
 - Radio Frequency
 - Thermal/Heat
 - Ultrasound/Sonophoresis
 - Transdermal Sprays

Transdermal Delivery Therapeutic Markets – Analysis and Market Data

- Contraception
- Cardiovascular
 - Angina
 - Hypertension
- Hormone Replacement Therapy
 - Estrogen
 - Testosterone
- Local Anesthesia
- Neurology
 - ADHD
 - Alzheimer's
 - Depression
 - Migraine
 - Motion Sickness
 - CINV
 - Parkinson's
- Pain Management
 - Evolution in Pain Management Guidelines
 - Cancer Breakthrough Pain
 - Neuropathic Pain
- Urology

Emerging Patch Therapeutics – Opportunity and Risk Assessment

- Addiction
- Antiviral
- Asthma
- Diabetes

Neurology
Oncology
Osteoporosis
Reproductive Medicine
Sexual Dysfunction
Vaccines

Profiles of Marketed Transdermal Products

Buprenorphine
Clonidine
Diclofenac
Estradiol
Estradiol/Levonorgestrol
Estradiol/Norethindrone acetate
Estradiol/Noethisterone
Estradiol/Norelgestromin
Fentanyl
Granisetron
Lidocaine
Methylphenidate
Nitroglycerin
Norelgestromin
Oxybutynin
Rivastigmine
Rotigotine
Scopolamine
Selegiline
Sumatriptan
Testosterone

Profiles of Products in Development for Delivery via Transdermal Systems

Acyclovir
Bupivacaine
Buprenorphine
Clomiphene
Capsaicin
Declofenac
Dexamethasone
Donepezil
Fentanyl
Granisetron
Insulin
Ketoprofen
Lisuride
Mecamylamine
PTH
Ropinirole
Sufentanil
Testosterone
Varenicline

Market Factors

FDA Regulations
Rx-to-OTC Switching
New Patch Technologies
Skin Patch Revenue Models

Market Sector Participant Profiles

3M
Acino/Novosis
Actavis
AGI Therapeutics
Alpharma (King)
Amarin
Antares
Applied Pharma Research
Auxillium
Aveva Drug Delivery
Axxonis
Azur Pharma
Bayer Healthcare
Biosante
Cerimon
DURECT
Endo
EpiCept
Ferring
Genetic Immunity
Grunenthal
Hisamitsu (see also Noven)
IDEA AG
Institut Biochimique
Intercell
Janssen
Jazz Pharmaceuticals
KV Pharma
Lavipharm
Lilly
LTS Lohmann
Mylan
Mundipharma KK
NeuroGesX
Nexmed
Norpharma A/S
Novartis
Noven (see also Hisamitsu)
NuPathe
Nuvo Research
Nycomed
Pfizer
Phosphagenics
Prostraken
Shire
Schwarz
Solvay
Somerset
SymBio
Teikoku
Teva
Travanti Pharma (See also Teikoku)
Transdel
TransPharma Medical
UCB
Valeritas
Vivus
Vyteris
Watson Pharmaceuticals
Winston Laboratories
Xel Pharmaceuticals
Zars
Zosano

Demographic Shifts Affecting healthcare Administration (2000 – 2050)
FDA-Approved Transdermal Products
Pipeline Transdermal Products in Development
Worldwide Patch Manufacturing Capacity by Company
Active Transdermal Drug Delivery – Relative Risk Assessment and Market Share Projection (2012)
Partnership Alliances of Transdermal Patch Manufacturers
Global Transdermal Patch Product Shipments by Indication (2008)
Forecast Global Transdermal Patch Product Shipments by Indication (2012)
Transdermal Estradiol Patches – Global Shipments by Manufacturer (2008 to 2012)
Transdermal Fentanyl - Branded vs Generic Sales (2002 to 2008)
Transdermal Fentanyl – Historical Shipments and Forecast by Company – Worldwide (2006 to 2012)
Transdermal Pain Management, Narcotic Drug Class, Worldwide Revenue Forecast (2006 to 2012)
Transdermal Pain Management, NSAID Drug Class, Worldwide Revenue Forecast (2006 to 2012)
Transdermal Pain Management, Local Anesthetic, Worldwide Revenue Forecast (2006 to 2012)
Transdermal Pain Management, Narcotic Drug Class, Worldwide Revenue Forecast by Region (2006 to 2012)
Transdermal Pain Management, NSAID Drug Class, Worldwide Revenue Forecast by Region (2006 to 2012)
Transdermal Pain Management, Local Anesthetic, Worldwide Revenue Forecast by Region (2006 to 2012)
Transdermal Pain Patch Products, Worldwide Revenue Forecast (2006 to 2012)
Transdermal Pain Gel Products, Worldwide Revenue Forecast (2006 to 2012)
Transdermal Pain Management, Worldwide Market Share, 2008
Transdermal Pain Management, Regional Market Share, 2008
Transdermal Pain Management, Worldwide Market Share, Forecast 2012
Transdermal Pain Management, Regional Market Share, Forecast 2012
Transdermal CNS Therapeutics, Worldwide Revenue Forecast by Drug Class (2006 to 2012)
Transdermal CNS Therapeutics, Worldwide Revenue Forecast by Indication (2006 to 2012)
Transdermal CNS Therapeutics, Worldwide Revenue Forecast by Region (2006 to 2012)
Transdermal CNS Therapeutics, Worldwide Revenue Forecast (2006 to 2012)
Transdermal CNS Therapeutics, Worldwide Revenue Forecast by Company (2006 to 2012)
Transdermal CNS Therapeutics, Worldwide Market Share, 2008
Transdermal CNS Therapeutics, Regional Market Share, 2008
Transdermal CNS Therapeutics, Worldwide Market Share, Forecast 2012
Transdermal CNS Therapeutics, Regional Market Share, Forecast 2012
Transdermal Hormone Replacement, Worldwide Revenue Forecast by Drug Class (2006 to 2012)
Transdermal Hormone Replacement, Worldwide Revenue Forecast by Indication (2006 to 2012)
Transdermal Hormone Replacement, Worldwide Revenue Forecast by Region (2006 to 2012)
Transdermal Hormone Replacement, Worldwide Revenue Forecast (2006 to 2012)
Transdermal Hormone Replacement, Worldwide Revenue Forecast by Company (2006 to 2012)
Transdermal Hormone Replacement, Worldwide Market Share, 2008
Transdermal Hormone Replacement, Regional Market Share, 2008
Transdermal Hormone Replacement, Worldwide Market Share, Forecast 2012
Transdermal Hormone Replacement, Regional Market Share, Forecast 2012
Transdermal Cardiovascular Drugs, Worldwide Revenue Forecast by Drug Class (2006 to 2012)
Transdermal Cardiovascular Drugs, Worldwide Revenue Forecast by Indication (2006 to 2012)
Transdermal Cardiovascular Drugs, Worldwide Revenue Forecast by Region (2006 to 2012)
Transdermal Cardiovascular Drugs, Worldwide Revenue Forecast (2006 to 2012)
Transdermal Cardiovascular Drugs, Worldwide Market Share, 2008
Transdermal Cardiovascular Drugs, Worldwide Market Share, Forecast 2012
CNS Drugs – Transdermal IP and Patent Summary
Transdermal Patch Manufacturing – Market Share by Company
Transdermal Gels – Global Market Share by Company (2008)
Transdermal Gels – Global Market Share Forecast (2012)
Technology Alliances – Relationships and Dependencies
Sourcing Alliances – Relationships and Dependencies
Marketing Alliances – Relationships and Dependencies

Feature Summary

- Provides detailed analysis of marketed transdermal delivery products and assessments of 36 pipeline candidates
- Analyzes transdermal delivery market segments, therapeutic indications, market dynamics and market demographics
- Assesses therapeutic demand drivers and risk factors
- Analyzes design factors, material selection issues, technologies and market development issues
- Charts product data, market share, and forecasts by drug class to 2012
- Profiles transdermal delivery sector participants, their product development activities, business strategies, and corporate alliances and affiliations
- Assesses the importance of pharma-device alliances and design partnerships on pen injector products
- Evaluates the impact of economic, technology, and regulatory factors

Report Format and Availability

This report is available electronic format. A site license for a single physical location and an Enterprise license are also available.

Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address. Orders which are not prepaid must indicate the billing address. There is no charge for handling and shipping for destination addresses within the continental US.

Payment

We accept the following forms of payment:

Company Check: Please make checks payable to 'Greystone Associates'

Credit Cards: We accept MasterCard, Visa and American Express

Wire Transfers: See 'Wire Transfers' below for more information

Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer. There is a \$50 per copy shipping and handling charge for international shipments.

Wire Transfers: TD Banknorth
300 Franklin Street
Manchester, NH 03103
(Call for Account Information)

Mailing Address: Greystone Associates
Client Services
P.O. Box 1362
Amherst, NH 03031

Transdermal Drug Delivery: Patches, Gels, Active Systems, Therapeutics, Markets and Forecasts

Select	Format	Price (U.S. funds)	Total
<input type="checkbox"/>	Electronic	\$4,500.00	
<input type="checkbox"/>	Site License	\$6,000.00	
<input type="checkbox"/>	Enterprise License	\$9,000.00	
Total Payment (U.S. funds)			

Method of Payment: Company Check    Wire Transfer (International)

Card Number: _____ Name on Card _____

Expiration Date: _____ CVV _____ Signature _____

Billing Information	Shipping Information
Name:	<input type="checkbox"/> Click here if same as Billing Information Name:
Title:	Title:
Company:	Company:
Street Address:	Street Address:
City,State/Province:	City,State/Province:
Country/Postal Code:	Country/Postal Code:
Phone:	Phone:
Fax:	Fax:
Email:	Email: